BR112014016338A8 - polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos - Google Patents

polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos

Info

Publication number
BR112014016338A8
BR112014016338A8 BR112014016338A BR112014016338A BR112014016338A8 BR 112014016338 A8 BR112014016338 A8 BR 112014016338A8 BR 112014016338 A BR112014016338 A BR 112014016338A BR 112014016338 A BR112014016338 A BR 112014016338A BR 112014016338 A8 BR112014016338 A8 BR 112014016338A8
Authority
BR
Brazil
Prior art keywords
polymers
conjugates
polyoxazoline
moiety
therapeutic
Prior art date
Application number
BR112014016338A
Other languages
English (en)
Other versions
BR112014016338B1 (pt
BR112014016338A2 (pt
Inventor
Hoogenboom Richard
Original Assignee
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2012/050001 external-priority patent/WO2012057628A2/en
Application filed by Univ Gent filed Critical Univ Gent
Publication of BR112014016338A2 publication Critical patent/BR112014016338A2/pt
Publication of BR112014016338A8 publication Critical patent/BR112014016338A8/pt
Publication of BR112014016338B1 publication Critical patent/BR112014016338B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0233—Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/02—Polyamines

Abstract

resumo polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos a presente invenção se refere a polímeros de poli(2-oxazolina) funcionalizados, que são muito adequados como um transportador e/ou veículo (conjugado) de liberação de drogas, tais como moléculas terapêuticas pequenas e bio- farmacêuticas. esses polímeros são caracterizados pelo fato de conterem unidades de repetição que são representadas pela seguinte fórmula -[n(r1)-(chr2)m]-, em que r1 é r3- (chr4)n-conh-r5; r2 é selecionado a partir de h e alquila c1-5 opcionalmente substituído; r3 é ch2, co, c(o)o, c(o)nh ou c(s)nh; r4 é selecionado a partir de h e alquila c1-5 opcionalmente substituído; r5 é h, um grupo alquila c1-5; arila ou um radical que compreende um grupo funcional que pode ser utilizado para a conjugação; m é 2 ou 3; e n é 1 a 5 ou n é 0 e r3 é ch2. a invenção se refere ainda a um conjugado destes polímeros de polioxazolina com pelo menos uma porção ativa, tal como uma porção terapêutica, uma porção de direcionamento e/ou uma porção de diagnóstico, bem como ao uso destes conjugados no tratamento terapêutico ou tratamento profilático ou de diagnóstico de uma doença ou distúrbio.
BR112014016338-3A 2012-01-02 2012-12-28 polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos BR112014016338B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NLPCT/NL2012/050001 2012-01-02
PCT/NL2012/050001 WO2012057628A2 (en) 2011-01-04 2012-01-02 Cross-linked polymers and implants derived from electrophilically activated polyoxazoline
EP12159986 2012-03-16
EP12159986.4 2012-03-16
PCT/NL2012/050933 WO2013103297A1 (en) 2012-01-02 2012-12-28 Polyoxazoline polymers and methods for their preparation, conjugates of these polymers and medical uses thereof

Publications (3)

Publication Number Publication Date
BR112014016338A2 BR112014016338A2 (pt) 2017-06-13
BR112014016338A8 true BR112014016338A8 (pt) 2017-07-04
BR112014016338B1 BR112014016338B1 (pt) 2021-01-26

Family

ID=48745312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016338-3A BR112014016338B1 (pt) 2012-01-02 2012-12-28 polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos

Country Status (7)

Country Link
US (1) US9180202B2 (pt)
EP (1) EP2800773B1 (pt)
JP (1) JP6159973B2 (pt)
CN (1) CN104024306B (pt)
BR (1) BR112014016338B1 (pt)
ES (1) ES2661461T3 (pt)
WO (1) WO2013103297A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015011743A (es) * 2013-03-15 2016-04-04 Basf Se Un agente quelante de polioxazolina.
BR112017000911B1 (pt) * 2014-07-18 2023-04-11 Universiteit Gent Método para preparação de polímeros uniformes de iminoéter cíclico tendo massa molar elevada
US11027026B2 (en) 2014-10-16 2021-06-08 Canon Kabushiki Kaisha Polymer, and contrast agent for photoacoustic imaging, including the polymer
EP3442501A1 (en) 2016-04-15 2019-02-20 Fairhaven Health, LLC Compositions and methods for maintaining or enhancing homeostasis or function of female lower reproductive tract
ES2808943T3 (es) 2016-07-01 2021-03-02 Univ Gent Poli(imino éter(es) cíclico(s))
EP3510080A1 (en) * 2016-09-12 2019-07-17 Dow Global Technologies, LLC Polymer including troger's base and isatin moieties and having intrinsic microporosity
WO2019175434A1 (en) 2018-03-16 2019-09-19 Universiteit Gent Drug formulations comprising polyoxazolines as matrix excipient
EP3802632A1 (en) * 2018-05-24 2021-04-14 Universiteit Gent Amidation of polymers containing ester side chains using functionalized amines
BR112022001554A2 (pt) * 2019-07-30 2022-03-22 Gatt Tech B V Copolímero de polioxazolina, uso do copolímero, produto médico biocompatível e processo de preparação de copolímeros
WO2022069635A1 (en) 2020-09-30 2022-04-07 Universiteit Gent Amorphous thermoresponsive polymers
EP4222248A1 (en) 2020-09-30 2023-08-09 Universiteit Maastricht 3d structures for cell growth
MX2023004263A (es) * 2020-10-19 2023-04-26 Univ Gent Polimeros de alilamido reticulables.
WO2023144228A1 (en) 2022-01-25 2023-08-03 Susos Ag Azide-functionalized copolymers
CZ2022167A3 (cs) * 2022-04-22 2023-11-01 Ústav makromolekulární chemie AV ČR, v. v. i. Polymerní konjugát pro blokování nespecifických interakcí v imunochemických stanoveních, způsob jeho výroby a jeho použití

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB760311A (en) 1951-10-06 1956-10-31 Allied Colloids Mfg Company Lt Improvements in and relating to derivatives of ethylene imine
US3442975A (en) 1967-01-11 1969-05-06 Allied Chem Polyimine/polycarbonamide graft polymers
US3996237A (en) * 1974-07-17 1976-12-07 The Dow Chemical Company Oxazoline- or oxazine-substituted acrylic esters
US5635571A (en) 1995-06-30 1997-06-03 Cornell Research Foundation, Inc. Polymerizable macromonomers and polymers prepared therefrom
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
WO2000033764A1 (en) 1998-12-04 2000-06-15 Pathak Chandrashekhar P Biocompatible crosslinked polymers
WO2000071600A1 (de) * 1999-05-19 2000-11-30 Basf Aktiengesellschaft Vernetzte, kondensierte basische aminosäuren enthaltende polymere und verfahren zu ihrer herstellung
DE10152407A1 (de) 2001-10-24 2003-05-08 Aesculap Ag & Co Kg Zusammensetzung aus mindestens zwei biokompatiblen chemisch vernetzbaren Komponenten
US7300738B2 (en) 2003-02-10 2007-11-27 Fujifilm Corporation Azolinyl acetic acid derivative and azolinyl acetic acid derivative containing recording material
JP2005161698A (ja) 2003-12-03 2005-06-23 Fuji Photo Film Co Ltd 記録材料
WO2006083260A2 (en) 2004-04-28 2006-08-10 Angiotech Biomaterials Corporation Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
WO2006034128A2 (en) 2004-09-17 2006-03-30 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
US8088884B2 (en) 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
JP5514736B2 (ja) * 2008-01-11 2014-06-04 セリナ・セラピユーテイツクス・インコーポレーテツド ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
JP5642673B2 (ja) * 2008-07-10 2014-12-17 セリナ・セラピユーテイツクス・インコーポレーテツド 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US9855372B2 (en) 2008-10-17 2018-01-02 Sofradim Production Auto-sealant matrix for tissue repair
JP2011102332A (ja) * 2009-11-10 2011-05-26 Toray Ind Inc 水溶性ナノ粒子複合体を形成するための両親媒性ポリマー
US8907047B2 (en) * 2010-06-25 2014-12-09 Toray Industries, Inc. Water-soluble polymer and water-soluble nanoparticle composite

Also Published As

Publication number Publication date
US9180202B2 (en) 2015-11-10
JP6159973B2 (ja) 2017-07-12
EP2800773B1 (en) 2017-12-13
BR112014016338B1 (pt) 2021-01-26
JP2015503556A (ja) 2015-02-02
BR112014016338A2 (pt) 2017-06-13
CN104024306A (zh) 2014-09-03
WO2013103297A1 (en) 2013-07-11
CN104024306B (zh) 2017-06-13
ES2661461T3 (es) 2018-04-02
US20150025196A1 (en) 2015-01-22
EP2800773A1 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
BR112014016338A8 (pt) polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos
MA42232A (fr) Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA200970446A1 (ru) Связывающиеся с альбумином молекулы и их применение
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
RU2010129238A (ru) Применение производных изотиоцианата в качестве противомиеломных средств
EP1988910A4 (en) CONJUGATES OF POLYMERS CONTAINING ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE AND THEIR PREPARATION
BR112014026730A2 (pt) conjugados fármaco-ligante de dr5
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
EA200970931A1 (ru) Аналоги гетероариламидов
EA201591027A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
BR112013031510A2 (pt) [1,3]oxazinas
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
BR112014012056A8 (pt) compostos farmacêuticos
BR112012017556A2 (pt) formulações de torta liofilizada
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
BR112014011831A2 (pt) copolímero em bloco tendo grupo ácido fenilborônico nele introduzido e o uso deste
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C08G 73/02 (2006.01), A61K 47/34 (2017.01), C08L 7

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2012, OBSERVADAS AS CONDICOES LEGAIS.